

# **APSMI NEWSLETTER**

## **April 2023**

### **Contents:**

#### **World Topics:**

- **Asia: E-labeling position paper adopted at the 12th APAC**
- **Malaysia: E-labeling guideline was issued**
- **WHO: Alert of the risk of anaphylactic reactions who have taken pholcodine containing products was issued**
- **WHO: proposes updated excipient GMPs in wake of contaminated cough syrup**
- **USA: “Over-the-Counter (OTC) Drug Review on OTC Monograph Reform in the CARES Act” and “Draft Guidance for Over-the-Counter Monograph Order Requests (OTC-OMORs): Format and Content” were issued**





**ASIA-PACIFIC SELF-MEDICATION INDUSTRY**  
ITOHPIA IWAMOTOCHO 1-CHOME BLDG. 4<sup>TH</sup> FLOOR  
1-8-15, IWAMOTOCHO, CHIYODA-KU, TOKYO 101-0032, JAPAN

## World Topics

### **Asia: E-labeling position paper adopted at the 12th APAC**

The 12<sup>th</sup> Asia Partnership Conference of Pharmaceutical Associations (APAC) (organized and hosted by JPMA) was held in Tokyo on 18 April 2023.

APAC e-labeling position paper for early implementation of e-labeling in Asian countries and for a unified approach was adopted.

The APAC E-labeling position paper is available at the following URL:

[https://apac-asia.com/images/elabeling/APAC\\_e-Labeling\\_PositionPaper.pdf](https://apac-asia.com/images/elabeling/APAC_e-Labeling_PositionPaper.pdf)

The program and PPTs of the 12<sup>th</sup> APAC are available at the following URL:

<https://12th-apac.com/index.html>

### **Malaysia: E-labeling guideline was issued**

E-labeling guideline was issued by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia on April 11, 2023 (It is not a mandatory requirement).

The Implementation schedule is explained in detail in the presentation materials for the 12th APAC mentioned above.

The guideline is available at the following URL:

In Malay:

<https://www.npra.gov.my/index.php/en/directive-general/1527484-direktif-berkenaan-pelaksanaan-electronic-labelling-e-labelling-ke-atas-produk-farmaseutikal-di-malaysia.html>

English translation:

<https://www.npra.gov.my/easyarticles/images/users/1047/Lampiran-A-Guideline-on-E-Labeling-for-Pharmaceutical-Products-in-Malaysia.pdf>

### **WHO: Alert of the risk of anaphylactic reactions who have taken pholcodine containing products was issued**

On 31 March 2023, The World Health Organization (WHO) issued an alert to health-care professionals and regulatory authorities of the risk of anaphylactic reactions in people who have taken pholcodine-containing products at least 12 months prior to surgical procedures involving the administration of general anaesthesia with neuromuscular blocking agents (NMBAs).

The alert is available at the following URL:

[Prior use of pholcodine-containing cough and cold remedies and risk of perioperative anaphylactic reactions to neuromuscular blocking agents \(NMBAs\) \(who.int\)](https://www.who.int/news/item/31-03-2023-prior-use-of-pholcodine-containing-cough-and-cold-remedies-and-risk-of-perioperative-anaphylactic-reactions-to-neuromuscular-blocking-agents-nmbas)



**ASIA-PACIFIC SELF-MEDICATION INDUSTRY**  
ITOHPIA IWAMOTOCHO 1-CHOME BLDG. 4<sup>TH</sup> FLOOR  
1-8-15, IWAMOTOCHO, CHIYODA-KU, TOKYO 101-0032, JAPAN

**WHO: proposes updated excipient GMPs in wake of contaminated cough syrup**

WHO recently proposed updated guidance to assist pharmaceutical manufacturers in assessing the quality of excipients after child deaths were reported in several countries linked to contaminated cough syrups containing unacceptable levels of diethylene glycol (DEG) and ethylene glycol (EG) in their formulations.

The guideline is available at the following URL:

[https://cdn.who.int/media/docs/default-source/health-products-policy-and-standards/qas23\\_921\\_gmp\\_for\\_excipients\\_pharmaceutical\\_products\\_public\\_consultation.pdf?sfvrsn=c9ef88da\\_3](https://cdn.who.int/media/docs/default-source/health-products-policy-and-standards/qas23_921_gmp_for_excipients_pharmaceutical_products_public_consultation.pdf?sfvrsn=c9ef88da_3)

**USA: “Over-the-Counter (OTC) Drug Review on OTC Monograph Reform in the CARES Act” and “Draft Guidance for Over-the-Counter Monograph Order Requests (OTC-OMORs): Format and Content” were issued**

The US FDA has published a review on OTC Monograph Reform in the CARES Act on 12 April 2023.

In addition, US FDA released “Draft Guidance for Over-the-Counter Monograph Order Requests (OTC-OMORs): Format and Content” on 13 April 2023.

The review is available at the following URL:

<https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs/over-counter-otc-drug-review-otc-monograph-reform-cares-act>

The draft guidance is available at the following URL:

<https://www.federalregister.gov/documents/2023/04/13/2023-07767/over-the-counter-monograph-order-requests-format-and-content-draft-guidance-for-industry>